SRZNW
MaterialsSurrozen Inc - Warrants (01/08/2026)
Live · NASDAQ · May 9, Close
What's Moving SRZNW Today?
No stock-specific AI insight has been generated for SRZNW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.02
Fundamentals
Trading
SRZNW News
13 articles- Surrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 28, 2026
- Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 15, 2026
- Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Yahoo Finance·Apr 14, 2026
- Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 23, 2026
- Surrozen to Present at Upcoming Healthcare Investor ConferenceYahoo Finance·Feb 25, 2026
- Surrozen Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 7, 2025
- Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Sep 4, 2025
- Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the companyYahoo Finance·Aug 30, 2025
- Surrozen Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 8, 2025
- We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthYahoo Finance·Jul 1, 2025
- Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayYahoo Finance·May 14, 2025
- Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 9, 2025
All 13 articles loaded
Price Data
52-Week Range
$0.02
Fundamentals
Trading
About Surrozen Inc - Warrants (01/08/2026)
Surrozen Inc. is an innovative biotechnology company focused on developing breakthrough therapeutics for complex diseases through its proprietary platform emphasizing targeted biology. By specializing in antibody therapeutics for tissue-specific delivery, Surrozen aims to effectively modulate critical biological pathways linked to various diseases. The company boasts a robust pipeline of candidates across multiple development stages, reflecting its commitment to transformative treatment solutions. With a highly experienced team and strategic collaborations, Surrozen is poised to significantly advance the field of regenerative medicine, potentially redefining standard care for patients.